Krystal Biotech, Inc. (KRYS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$300.25-3.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · KRYS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 22.6% |
| Our one-year growth estimate | diamond | 31.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
KRYS — litigation filed
Dated 2026-07-21
and the copy of the image of the corneal epithelial defect closure from the patent prosecution record that is attached to this Current Report on Form 8-K as Exhibit 99.1 shall not be (i) deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended , or otherwise subject to the liabilities of that section, or (ii) incorporated by reference into any filing with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, re…
Why it matters: The plan may use natural history data to support the study. FDA alignment is due in Q4 2026.
Watch forIn Q4 2026, Krystal reports FDA agreement on the KB407 study design and analysis plan. A 2027 study start stays on track.
Also watch forKrystal reports no FDA alignment in Q4 2026, or says the planned 2027 study start is delayed.
Why it matters: Both launches would extend VYJUVEK sales in Europe. Krystal still described them as planned in Q2.
Supportive ifKrystal confirms commercial launches in both Spain and Italy before the end of 2026.
Worry ifEither launch is delayed beyond 2026, or Krystal reports that a launch did not occur.
Why it matters: The range covers combined R&D and SG&A costs. Six-month costs rose from 2025, so full-year results will test the plan.
Watch forKrystal reports FY 2026 combined non-GAAP R&D and SG&A costs between $175 million and $195 million.
Also watch forKrystal reports costs above $195 million or below $175 million for FY 2026.
Why it matters: Q2 global revenue grew 24% year over year. A slower pace would weaken the recent growth signal.
Worry ifA later quarterly report shows VYJUVEK global revenue growth at or below 20% year over year.
Less concerning ifA later quarterly report shows VYJUVEK global revenue grew more than 20% year over year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $356 loss on $10,000 · 3.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,175 loss on $10,000 · 21.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: KB803 met its enrollment goal. The study tests whether it cuts corneal symptom days in DEB patients.
Watch forQ4 results show fewer average days per month with corneal abrasion symptoms on KB803 than on placebo.
Also watch forQ4 results show no symptom-day reduction on KB803 versus placebo, or the readout is delayed.